GREENWICH, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gabelli Funds will host its 17th Annual Specialty Chemicals Symposium in Midtown Manhattan, New York City on Thursday, March 19, 2026. The event will feature discussions with leading companies and organizations across the specialty chemicals ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as Specialty Chemicals investing. Attendees will also have the opportunity to participate in one-on-one meetings with ...

Quaker Houghton Fourth Quarter and Full Year 2025 Results Investor Conference Call Forward-Looking Statements Forward-Looking Statements This presentation contains "forward-looking statements" that fall under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and the Securities Act of 1933, as amended. These statements can be identified by the fact that they do not relate strictly to historical or current facts. We have based these forward-looking statements on assumptions, p ...

Core Viewpoint - Croda International reported strong 2025 results with increased sales and profits, alongside a three-year financial framework aimed at enhancing margins and cash generation by 2028 [1] Financial Performance - Sales rose 7% in constant currency to £1.7 billion, with patented ingredient sales increasing by 9% and a notable demand for innovation [2] - Adjusted operating profit increased by 8% to £295 million, while adjusted profit before tax also rose by 8% to £276 million, aligning with guidance [2] - Free cash flow reached £162 million, supported by reduced capital spending and lower working capital in the latter half of the year [2] - Net debt at year-end was £524 million, with a leverage ratio of 1.3x EBITDA [2] - The company proposed a final dividend of 63 pence, bringing the total annual dividend to 111 pence, a slight increase from the previous year [2] Segment and Regional Performance - In Q4, sales grew by 5% in constant currency, slightly exceeding expectations, with Consumer Care up 9% driven by Flavors and Fragrances and Beauty Actives [3] - Life Sciences sales increased by 8%, with Pharma achieving its strongest quarter due to higher excipient sales [3] - Crop protection sales rose by 12% in Q4, although growth is expected to slow in 2026 [3] - Industrial Specialties saw a decline of 19% compared to a strong prior-year performance [3] Full Year Segment Performance - For the full year, Consumer Care sales increased by 8%, with Flavors and Fragrances up 15% and Beauty Actives growing by 6% [4] - Life Sciences rose by 8%, with crop protection up 14% as demand rebounded after destocking [4] - Pharma growth was at 4%, which was below expectations due to U.S. policy impacts on vaccine adjuvant sales [4] - Industrial Specialties declined by 2%, with direct sales growth offsetting a decline with Cargill, which now represents 20% of Industrial Specialties sales [4] Regional Performance - Croda reported growth across all regions, led by EMEA with a 9% sales increase [5] - Asia lagged due to U.S. tariffs impacting customer exports in pharma and industrial markets [5] - North America showed improvement in the second half, supported by a recovery in the beauty sector [5]

Core Insights - The company achieved strong free cash flow of €350 million in 2025 despite a challenging market environment, with a focus on strategic and sustainability commitments [4][6] - Underlying net sales for 2025 were €4.3 billion, reflecting a 6.5% organic decline compared to 2024, while underlying EBITDA was €881 million, down 13.4% organically [6][14] - The company is committed to its "Essential chemistry" strategy, emphasizing cost savings and disciplined capital allocation to navigate market softness and geopolitical uncertainties [5][8] Financial Performance - Q4 2025 net sales were €995 million, a 12.3% decrease year-on-year, while FY 2025 net sales totaled €4,262 million, down 9.0% [2] - EBITDA for Q4 2025 was €169 million, a 33.9% decline year-on-year, with an EBITDA margin of 17.0% [2] - The underlying net profit from continuing operations was €306 million in 2025, compared to €445 million in 2024 [6] Cost Management and Strategic Initiatives - The company generated over €200 million in cost savings over the past two years, focusing on digitalization and simplification [5] - Structural cost savings initiatives contributed €101 million in 2025, with cumulative savings reaching €211 million [6] - Transformation expenses negatively impacted EBITDA by €27 million and free cash flow by €71 million in 2025 [6] Dividend and Future Outlook - A total proposed gross dividend of €2.43 per share is subject to shareholder approval, with a stable-to-increasing dividend policy confirmed [11] - For 2026, the company expects underlying EBITDA to be between €770 million and €850 million, with free cash flow projected to be at least €200 million [9][13] - The company anticipates continued geopolitical and macroeconomic challenges, impacting end-market demand and pricing pressure [9]

Core Points - The Annual General Meeting of Sika AG is scheduled for March 24, 2026, with all current Board members standing for re-election except Paul Schuler [2][6] - The Board proposes to increase the gross dividend by 2.8% to CHF 3.70 per share, up from CHF 3.60 the previous year [3][6] - The complete agenda for the meeting will be sent to shareholders on February 25, 2026, and published in the Swiss Official Gazette of Commerce [4] Company Profile - Sika is a leading specialty chemicals company focused on bonding, sealing, damping, reinforcing, and protection products for the construction and industrial sectors [5] - The company operates in 102 countries, with over 400 production facilities, and employs approximately 33,700 people [5] - In 2025, Sika reported annual sales of CHF 11.20 billion, highlighting its significant market presence [5]

Core Viewpoint - The Chemours Company (CC) shares have increased by approximately 9% over the past year, but this figure conceals significant volatility, with share prices fluctuating between $9 and $22. Following a strong performance, the stock experienced a 17% decline last week due to weaker Q4 earnings [1]. Company Performance - The Chemours Company's stock has shown a notable increase of about 9% year-over-year, indicating some level of investor confidence despite the volatility [1]. - The stock has traded within a wide range, from $9 to $22, highlighting the instability in its market performance [1]. - A significant drop of 17% occurred last week, attributed to disappointing Q4 earnings results [1].

Advanced Performance Materials business president to help guide SEMI's efforts supporting North America's semiconductor innovation and supply chain resilience WILMINGTON, Del., Feb. 23, 2026 /PRNewswire/ --The Chemours Company (Chemours) (NYSE: CC), a global chemistry company, today announced that Gerardo Familiar, President of the company's APM business, has been appointed to the SEMI North America Advisory Board (NAAB). SEMI is a global industry association serving thousands of member companies across the ...

Rojo also emphasized capital allocation discipline, noting Stepan generated positive free cash flow in 2025, reduced net debt, and improved its leverage ratio from 2.8x to 2.5x by year-end.Despite what management described as a challenging macroeconomic environment for the chemical sector—including raw material inflation and tariff impacts—Rojo said the company delivered full-year adjusted EBITDA of $199 million , up 6% year over year. Organic volume increased 2% for the year, driven by growth in crop produ ...

Chief Financial Officer Scott Minder, who joined Mativ in January, said full-year 2025 net sales were “just under $2 billion,” up 2.5% organically versus the prior year. Adjusted EBITDA for 2025 was $225 million, up 3% year-over-year, and adjusted EPS was $0.70 compared with $0.62 in the prior year.She pointed to a cultural reset emphasizing speed, accountability, and closer alignment with customers. Singhal said the company shifted from a “defensive posture” to an “offensive one,” focusing on share gains a ...

Stepan Company Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Delivered 6% adjusted EBITDA growth in 2025 despite unprecedented raw material inflation, tariff impacts, and a challenging chemical sector macro environment. Performance was driven by disciplined pricing and favorable mix in crop productivity, oilfield, and specialty products, which offset softer demand in global consumer surfactants. Successfully commissioned the Pasadena alkoxylation facility, markin ...